Research
Hormonal
Statins reduce the risk of developing MASLD and progression to liver fibrosis, and may reduce cardiovascular events in MASLD patients, despite not directly reducing liver fat.
If you have fatty liver and high cardiovascular risk, you should take statins. They do not remove liver fat, but they reduce inflammation and fibrosis, and significantly lower your risk of heart attacks and strokes. The benefits outweigh the theoretical risks.
GoodSupportsHIGH confidence
Statins do not appear to reduce liver fat per se, but might mitigate the risk linked with MASLD through their lipid lowering, anti-inflammatory, antioxidant and anti-fibrotic effects
Why this rating
Supported by large population studies and RCTs using non-invasive scores, though histological data is limited.
Source
Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology
Paolo Raggi et al. · Atherosclerosis · 2024
DOI 10.1016/j.atherosclerosis.2024.117523
narrative_reviewCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →